Trial Profile
Phase I Study of GW685698X -A Randomized, Double Blind, Placebo Controlled, Parallel-group, Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Dose From a Novel Dry Powder Device in Healthy Japanese Male Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Fluticasone furoate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Perennial allergic rhinitis; Seasonal allergic rhinitis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 11 Sep 2009 New trial record